A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)

ABSTRACT:

SUBMITTER: Long G 

PROVIDER: S-EPMC4645515 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature